Skip to main content
AVR
NASDAQ Industrial Applications And Services

Anteris Technologies Secures $320M Capital, Including Strategic Investment from Medtronic

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$6.5
Mkt Cap
$270.668M
52W Low
$2.34
52W High
$8.79
52W Position info
178% above low
Off High info
26% below high
Rel. Volume info
8.5× avg
Market data snapshot near publication time

AVR has more than doubled off its 52-week low of $2.34 on elevated volume (8.5× avg).

Summary

Anteris Technologies Global Corp. announced a $320 million capital raise, comprising a public offering and a $90 million strategic investment from Medtronic plc, to fund its pivotal clinical trial and growth initiatives.


Key Events · Financing and Capital Events · AVR

  • Substantial Capital Raise Completed

    The company completed a $320 million capital raise, consisting of a $230 million underwritten public offering and a $90 million private placement.

  • Strategic Investment by Medtronic

    Medtronic plc, through its subsidiary Covidien Group S.à r.l., made a $90 million strategic investment, acquiring 15,652,173 shares at $5.75 per share. This includes potential future collaboration and a non-voting board observer right for Medtronic.

  • Funding for Pivotal Clinical Trial

    Proceeds will primarily fund the DurAVR® THV global pivotal trial (PARADIGM Trial) and expand manufacturing capabilities, crucial for advancing the company's lead product.

  • Significant Dilution at a Discounted Price

    The offering was priced at $5.75 per share, a discount to the current market price, resulting in substantial dilution for existing shareholders but providing critical capital.


Analysis · AVR · Industrial Applications And Services

Anteris Technologies Global Corp. has completed a substantial capital raise totaling $320 million, a critical event for a company of its size. This includes a $230 million underwritten public offering and a $90 million strategic private placement from Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc. The offering was priced at $5.75 per share, a discount to the current market price of $6.50. The proceeds are earmarked to support the next stage of growth, advance the company's clinical strategy, fund the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial (PARADIGM Trial), and expand manufacturing capabilities. The involvement of Medtronic, a major medical technology company, as a strategic investor provides significant validation for Anteris's technology and future prospects, including potential collaboration opportunities in manufacturing, co-development, and co-commercialization. While the capital raise is highly dilutive, it provides essential funding and strategic backing to de-risk the company's critical clinical development pathway.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AVR was trading at $6.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $270.7M. The 52-week trading range was $2.34 to $8.79. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AVR - Latest Insights

AVR
Nov 10, 2026, 5:20 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $5.90
Real-time Price: $5.09 info
Change: -$0.810 (-14%) info
Market Cap: $486.492M info
AVR
Nov 10, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.89
Real-time Price: $5.09 info
Change: -$0.800 (-14%) info
Market Cap: $486.492M info
AVR
Oct 06, 2026, 6:18 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $7.51
Real-time Price: $5.09 info
Change: -$2.42 (-32%) info
Market Cap: $486.492M info
AVR
Oct 01, 2026, 8:09 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $7.61
Real-time Price: $5.09 info
Change: -$2.52 (-33%) info
Market Cap: $486.492M info
AVR
Aug 12, 2026, 6:13 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $8.84
Real-time Price: $5.09 info
Change: -$3.75 (-42%) info
Market Cap: $486.492M info